AYTU vs. CNXC
AYTU (Aytu BioPharma, Inc.) and CNXC (Concentrix Corporation) are both stocks. AYTU operates in Drug Manufacturers - Specialty & Generic (Healthcare), while CNXC operates in Information Technology Services (Technology). Over the past 5 years, AYTU returned -53.73%/yr vs -27.31%/yr for CNXC. At a 0.18 correlation, their price movements are largely independent.
Performance
AYTU vs. CNXC - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AYTU achieves a -11.92% return, which is significantly higher than CNXC's -32.63% return.
AYTU
- 1D
- 1.78%
- 1M
- -8.40%
- YTD
- -11.92%
- 6M
- 2.23%
- 1Y
- 14.50%
- 3Y*
- 12.70%
- 5Y*
- -53.73%
- 10Y*
- —
CNXC
- 1D
- -1.58%
- 1M
- 12.81%
- YTD
- -32.63%
- 6M
- -26.68%
- 1Y
- -49.86%
- 3Y*
- -29.25%
- 5Y*
- -27.31%
- 10Y*
- —
AYTU vs. CNXC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
AYTU Aytu BioPharma, Inc. | -11.92% | 52.94% | -40.14% | -24.87% | -86.00% | -77.42% | -34.18% |
CNXC Concentrix Corporation | -32.63% | -1.39% | -55.03% | -25.36% | -24.91% | 81.22% | 23.37% |
Correlation
The correlation between AYTU and CNXC is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.16 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Nov 24, 2020 | 0.18 |
Fundamentals
AYTU:
$24.07M
CNXC:
$1.68B
AYTU:
-$2.91
CNXC:
-$21.33
AYTU:
0.47
CNXC:
0.17
AYTU:
0.68
CNXC:
0.60
AYTU:
$56.60M
CNXC:
$9.95B
AYTU:
$36.14M
CNXC:
$3.27B
AYTU:
-$27.34M
CNXC:
-$944.68M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AYTU vs. CNXC — Risk / Return Rank
AYTU
CNXC
AYTU vs. CNXC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Aytu BioPharma, Inc. (AYTU) and Concentrix Corporation (CNXC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| AYTU | CNXC | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.08 | ||
| Sortino ratioReturn per unit of downside risk | +1.76 | ||
| Omega ratioGain probability vs. loss probability | 1.10 | 0.87 | +0.23 |
| Calmar ratioReturn relative to maximum drawdown | 0.41 | -0.81 | +1.22 |
| Martin ratioReturn relative to average drawdown | 0.97 | -1.34 | +2.31 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| AYTU | CNXC | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.27 | -0.82 | +1.08 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.63 | -0.57 | -0.06 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.36 | -0.33 | -0.03 |
Drawdowns
AYTU vs. CNXC - Drawdown Comparison
The maximum AYTU drawdown since its inception was -100.00%, which is greater than CNXC's maximum drawdown of -87.86%. Use the drawdown chart below to compare losses from any high point for AYTU and CNXC.
Loading charts...
Drawdown Indicators
| AYTU | CNXC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -87.86% | -12.14% |
Max Drawdown (1Y)Largest decline over 1 year | -35.47% | -61.71% | +26.24% |
Max Drawdown (3Y)Largest decline over 3 years | -70.24% | -76.50% | +6.26% |
Max Drawdown (5Y)Largest decline over 5 years | -99.12% | -87.86% | -11.26% |
Current DrawdownCurrent decline from peak | -100.00% | -85.48% | -14.52% |
Average DrawdownAverage peak-to-trough decline | -95.15% | -47.65% | -47.50% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.92% | 37.32% | -22.40% |
Volatility
AYTU vs. CNXC - Volatility Comparison
The current volatility for Aytu BioPharma, Inc. (AYTU) is 14.09%, while Concentrix Corporation (CNXC) has a volatility of 15.12%. This indicates that AYTU experiences smaller price fluctuations and is considered to be less risky than CNXC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AYTU | CNXC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.09% | 15.12% | -1.03% |
Volatility (6M)Calculated over the trailing 6-month period | 33.39% | 51.98% | -18.59% |
Volatility (1Y)Calculated over the trailing 1-year period | 55.06% | 61.40% | -6.34% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 85.66% | 48.26% | +37.40% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 188.20% | 49.78% | +138.42% |
Dividends
AYTU vs. CNXC - Dividend Comparison
AYTU has not paid dividends to shareholders, while CNXC's dividend yield for the trailing twelve months is around 5.16%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
AYTU Aytu BioPharma, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
CNXC Concentrix Corporation | 5.16% | 3.27% | 2.87% | 1.15% | 0.77% | 0.14% |
Financials
AYTU vs. CNXC - Financials Comparison
This section allows you to compare key financial metrics between Aytu BioPharma, Inc. and Concentrix Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AYTU vs. CNXC - Profitability Comparison
AYTU - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported a gross profit of 7.60M and revenue of 12.41M. Therefore, the gross margin over that period was 61.2%.
CNXC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Concentrix Corporation reported a gross profit of 849.66M and revenue of 2.50B. Therefore, the gross margin over that period was 34.0%.
AYTU - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported an operating income of -4.06M and revenue of 12.41M, resulting in an operating margin of -32.8%.
CNXC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Concentrix Corporation reported an operating income of 118.56M and revenue of 2.50B, resulting in an operating margin of 4.7%.
AYTU - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported a net income of -5.62M and revenue of 12.41M, resulting in a net margin of -45.3%.
CNXC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Concentrix Corporation reported a net income of 21.59M and revenue of 2.50B, resulting in a net margin of 0.9%.
Frequently Asked Questions
AYTU and CNXC have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CNXC has higher volatility (15.12%) compared to AYTU (14.09%). In terms of maximum drawdown, AYTU dropped -100.00% vs CNXC's -87.86%.
AYTU currently has the higher Sharpe Ratio (0.27 vs -0.82), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AYTU and CNXC
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer